Pharma Trend
  • Pharma Trend
  • Pharma Award
    • Golden Tablet
    • Most innovative Product
    • Honorary Award
  • Pharma Ranking
  • Impressions
  • Sponsors & Partners
  • News
    • Gastroenterologists
    • Industry
    • Pain Therapists
    • Urologists

Incyte ranks 9th in Pharma Trend Ranking 2022

October 7, 2022 by Editorial staff

Incyte Biosciences is ranked 9th in the multidisciplinary “Best Pharmaceutical Companies Germany” 2022 ranking in the category “Large individual, medium-sized and international companies”. Infectopharm, Gedeon Richter, ALK-Abelló and Exeltis placed first this year. Incyte, a still relatively small but research-intensive biopharmaceutical company, has made it into the top 10 most innovative companies three times in recent years.

Incyte: pure research and innovation

In 2002, Incyte Inc. was founded in Wilmington, Delaware by a team of scientists, chemists and biologists researching immunology. The company’s mission was and still is to develop drugs for serious or life-threatening, sometimes rare, diseases for which no therapy is yet available. The focus is on the fields of oncology, inflammation and autoimmunity. Incyte has an extreme focus on science, with a large proportion of employees working in research and development of new compounds, particularly biologics and small and large chemical molecules. The company claims unique expertise in biomedicine and biochemistry, which has enabled it to create a diversified pipeline of clinical candidates as well as a portfolio of marketed drugs through proprietary development.

Incyte now employs around 1,500 people and has offices in the USA, Canada, Europe and Japan. The European headquarters, Incyte Biosciences International, is based in Morges, Switzerland. In Germany, Incyte Biosciences Germany GmbH is based in Munich. Sales in 2021 were $2.322 billion, an increase of 12% over the previous year. Investment in research and development is reported in the annual report at USD 1.458 billion, or 63% of sales – an exceptionally high percentage that characterises a company that is 100% committed to research and science.

Currently, Incyte offers the protein kinase inhibitor ponatinib (Iclusig®) in Germany, approved for certain forms of leukaemia (CML and Ph+ ALL).

With the kinase inhibitor pemigatinib (Pemazyre®), the first targeted therapeutic for certain subtypes of bile duct cancer came onto the market in May 2021. Cancer experts ranked Incyte’s “orphan drug” as the most innovative product in this indication in 2021. The monoclonal antibody tafasitamab (MINJUVI ®) is used to treat patients with B-cell lymphoma.

In the USA, Incyte markets its mainstay ruxolitinib (Jakafi®); in Germany, it is marketed by Novartis under the name Jakavi® for use in myelofibrosis and polycythaemia vera. Approval for ruxolitinib ointment for vitiligo (white spot disease) has been granted in the USA and is being sought in Europe.

Awards for Incyte for Innovation

Incyte first received the 2021 Most Innovative Product award for innovation and sustainability for Pemazyre®, the first targeted therapeutic for certain forms of bile duct cancer.

  • Pemazyre® (2021)
About the award ceremony

The awards were announced on 13 September 2022 at the Deutsches Museum in Munich. The keynote speech was given by the patron of the event, the Bavarian Minister of Health Klaus Holetschek, Bavarian State Ministry of Health and Care. The festive awards ceremony was hosted by TV presenter Tamara Sedmak (Sat 1, n-tv, N24).

Pharma Trend - The market research on innovation and sustainability

The basis for the ranking and the awards is the Pharma Trend benchmark study, which has been conducted annually in the Rx category among physicians in Germany since 2000 and since 2018 also in the OTC and Orphan Drugs categories, and since 2019 also in the Specialty Care category on behalf of the PharmaBarometer magazine (https://pharmabarometer.de/pharmabarometer/). In 2021, the study was expanded to include the categories “Diagnostics” and “Digital Health Applications”. With the expansion of Pharma Trend, companies in pharmaceuticals and medical technology are assessed on innovation and sustainability via their most important stakeholders – doctors, pharmacists and patients. This year, Pharma Trend was conducted online with 700 physicians, including allergists, general practitioners, dermatologists, gynaecologists, oncologists/haematologists, paediatricians and urologists, as well as 100 pharmacists and 600 patients.

Further information on Pharma Trend and the report volumes at https://pharma-trend.com/en/

Related posts:

  1. Bencard ranks 6th in Pharma Trend Ranking 2022
  2. Exeltis wins the “Most Innovative Product” award from gynaecologists twice and is ranked 4th in the Pharma Trend Ranking 2022
  3. Gilead ranks 7th in Pharma Trend Ranking 2022
  4. HAL Allergy ranks 7th in Pharma Trend Ranking 2022
Posted in: Allgemein Tagged: Ranking

Patronage

Melanie Huml, Minister of Bavarian State Ministry of Health and Care

Pharma Trend Image and Innovation Award

The survey of innovation and sustainability in pharmaceutical companies.

  • Deutsch
  • English

In the News

  • Ardent Health Partners, Inc. Updates Name to Ardent Health, Inc. May 24, 2025
  • Foundation Medicine Expands Immunohistochemistry (IHC) Testing Portfolio to Include MET IHC Testing May 23, 2025
  • $8.5 Bn Epigenetics Markets, 2021-2024 & 2025-2029 – Increasing Investment in Biomedical Research, Trends Towards Precision Medicine, Growing Interest in Liquid Biopsy – ResearchAndMarkets.com May 23, 2025
  • Cigna Adds Kerecis Intact Fish-Skin Grafts to Coverage Policy May 23, 2025
  • KindlyMD® Announces NASDAQ Ticker Symbol Change to ‘NAKA’ Effective May 23, 2025 May 23, 2025

Partners




Bio M ist Partner der Goldenen Tablette



Media Partnerships



Esanum ist Medienpartner der Goldenen Tablette







Sponsors & Partners:


ashfield
lucky7even is sponsor of Pharma Trend
Harris Interactive is partner of Pharma Trend
PharmaBarometer
Dorothea Küsters Life Science Communications
EQS-Group is sponsor of Pharma Trend
Esanum
MCC Logo
JJ Sustainability is sponsor of Pharma Trend
Healthcare Marketing Logo weiß
Bio-M
Gesdat Logo
tiny web is sponsor of Pharma Trend

Copyright © 2023 Eurecon Verlag GmbH

Imprint   |   Privacy Statement